- Home
- LUCY vs JAGX Comparison
LUCY vs JAGX Comparison
Compare LUCY & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | JAGX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8M | 5.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | LUCY | JAGX |
|---|---|---|
| Price | $1.03 | $6.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 77.0K | ★ 511.9K |
| Earning Date | 05-14-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,511,000.00 |
| Revenue This Year | $175.92 | $61.58 |
| Revenue Next Year | $205.56 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.95 | $0.22 |
| 52 Week High | $3.54 | $12.84 |
Technical Indicators
Market Signals| Indicator | LUCY | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 93.91 |
| Support Level | $1.01 | $1.77 |
| Resistance Level | $1.17 | N/A |
| Average True Range (ATR) | 0.04 | 0.20 |
| MACD | -0.00 | 0.65 |
| Stochastic Oscillator | 25.02 | 84.33 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.